



Correction to: Motixafortide: First Approval

Sheridan M. Hoy¹

Published online: 7 December 2023
© Springer Nature Switzerland AG 2023

Correction to: Drugs (2023) 83:1635–1643
<https://doi.org/10.1007/s40265-023-01962-w>

In the published PDF version, Section 2.1 Pharmacodynamics, second paragraph, sixth sentence, which currently reads:

In this study, a single subcutaneous injection of motixafortide (part 1: 1 mg/kg; part 2: 1.25 mg/kg) resulted in the collection of $\geq 2 \times 10^6$ CD34+ cells/kg within two leukapheresis procedures (primary endpoint) in 11 (85%) of 13 adult allogenic donors in part 1 and 11 (100%) of 11 of 13 adult allogenic donors in part 2. The collection of $\geq 2 \times 10^6$ CD34+ cells/kg in one leukapheresis procedure occurred in 11 (85%) of 13 allogenic donors and 8 (73%) of 11 allogenic donors, respectively.

Should read:

In this study, a single subcutaneous injection of motixafortide (part 1: 1 mg/kg; part 2: 1.25 mg/kg) resulted in the collection of $\geq 2 \times 10^6$ CD34+ cells/kg within two leukapheresis procedures (primary endpoint) in 11 (85%) of 13 adult allogenic donors in part 1 and 11 (100%) of 11 adult allogenic donors in part 2. The collection of $\geq 2 \times 10^6$ CD34+ cells/kg in one leukapheresis procedure occurred in 11 (85%) of 13 allogenic donors and 8 (73%) of 11 allogenic donors, respectively.

The original PDF version of the article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40265-023-01962-w>.

✉ Sheridan M. Hoy
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand